212. Back to Basics - Non-Melanoma Skin Cancer

Podcast: Oncology for the Inquisitive Mind · Michael Fernando and Josh Hurwitz

Opublikowano: 2026-08-29

If you like cemiplimab, you will like this episode. Since its introduction, cemiplimab has become the mainstay of treatment for cutaneous SCC, the most common non-melanoma skin cancer likely to attend an oncologist. Cemiplimab's scope is expanding; once reserved purely for the locally advanced or metastatic setting, evidence is emerging for its efficacy in the neoadjuvant setting. Today, Josh and Michael explore the use cases for cemiplimab in cSCC NOTE: this episode was NOT sponsored by cemiplimab! Studies Discussed in Today's Episode Migden et al. (2018) Gross et al (2023) <...